How to read a peptide study? A guide to critical assessment

First: which model was studied?

The most important question about any peptide study is also the most frequently overlooked: was the model a test tube (in vitro), an animal (animal), or a human (human)? Effect sizes in a cell culture cannot be transferred directly to animal models, and animal-model effects not directly to humans. A substance that doubles collagen synthesis in vitro in a fibroblast culture can be practically ineffective in a living human due to permeation, half-life or site-of-action reasons. A substance that improves neuroprotection in a mouse model of traumatic brain injury can fail in humans for pharmacokinetic or time-window reasons.

Practical tip: start every 'the study shows' claim with 'in which model?'. If the answer is 'in mice', that is a different statement than 'in a placebo-controlled trial of 1,961 adults'.

Second: what was the design?

Within human studies, a non-arbitrary hierarchy exists: randomised controlled trials (RCT) against placebo or active comparator are at the top, then non-randomised controlled trials, then open-label use studies, then case series, then individual case reports. The order does not reflect the intellectual quality of the researchers but the degree to which confounders, selection bias and placebo effects can distort the result.

In peptide studies this hierarchy is particularly important because many peptides come from the black-market discourse where 'users report …' is presented as evidence. User reports are anecdotal — a signal that can justify a systematic investigation, but no substitute for one.

Third: who wrote the protocol — and who paid?

Industry-funded studies are not per se wrong. But they have known systematic biases: active comparators are less often chosen, endpoints are defined so as to portray the substance favourably, negative studies are less often published. That is not a conspiracy theory but empirically documented research economics. In cosmetic peptides the overwhelming majority of published use studies are manufacturer-funded; with modern GLP-1 substances, the pivotal studies (STEP, SUSTAIN, SURMOUNT, SELECT) are manufacturer-funded but structurally independently conducted and published in independent journals.

Practical tip: a look at the 'funding' and 'conflict of interest' statements at the end of every PubMed entry. If all main authors are employed by the manufacturer and no independent data monitoring existed, that is a different study than one in which an independent academic group controlled the data.

Fourth: which endpoint was measured?

The choice of endpoint often decides more about the study result than the substance itself. There is an important distinction between clinical endpoints (death, cardiovascular event, documented symptom improvement) and surrogate endpoints (blood markers, imaging findings, scale scores). Surrogate endpoints are faster to measure, but their translation to clinical relevance is not self-evident. An LDL cholesterol reduction correlates with cardiovascular events — but not every substance that lowers LDL also reduces mortality. A BMI reduction is not the same as an improvement in quality of life or a reduction in obesity-associated endpoints.

Common surrogates in peptide studies: IGF-1 levels (for growth hormone therapies), wrinkle depth by image analysis (cosmetic), CT/MRI-measured visceral fat (tesamorelin), HbA1c (GLP-1 diabetes trials). These surrogates are established and valid, but they are not the clinical endpoints themselves.

Fifth: how large was the sample and how long the observation?

A study with 12 participants over 4 weeks can be mechanistically interesting, but it can neither capture rare side effects nor measure long-term effects. Pivotal approval trials of modern peptide medicines typically have 500-2000 participants over 26-104 weeks. For peptides with decades-long expected use (GLP-1, GnRH analogs), 10+-year safety data only become available years after first approval.

Practical tip: 'A small pilot study showed …' and 'In a 68-week trial with 1,961 participants …' are different classes of statement. The first is a signal, the second is evidence.

Sixth: has it been replicated?

A single study result — no matter how large the effect size — is not established knowledge. Established knowledge emerges from independent replication in different research groups, ideally with different study designs. In peptides there are some notable constellations: substances like semaglutide were tested across SUSTAIN/STEP/SELECT in thousands of participants across different indications — that is replication in a strong sense. Substances like BPC-157 have hundreds of preclinical studies but predominantly from a single principal research group — that is productivity, not replication. Substances from the Khavinson school (epitalon, thymalin) have a similar status: consistently positive findings from one tradition without independent Western replication.

Practical tip: 'Who, besides the original authors, has shown this?' is one of the most useful questions to ask any peptide claim.

Seventh: what was NOT investigated?

Perhaps the most important and most rarely asked question. Every study has deliberately chosen inclusion and exclusion criteria. A study in healthy men aged 25 to 45 says nothing about women, children, pregnant people, older people or patients with comorbidities. A 6-month study says nothing about effects after 5 years. A study that measures cardiovascular events says nothing about cognitive sequelae if these were not collected. Every gap in the evidence base remains a gap — even if marketing language papers over it.

Eighth: what does the study really say — and what is often made of it?

The classic pattern: a study shows that substance X in patients with condition Y under condition Z achieves an endpoint effect of magnitude E. From this, marketing or user language makes: 'X heals Y' or 'X is the most effective solution against Y'. Both are an over-extension — the study showed a statistically significant effect under certain conditions; it did not 'heal' and it did not substantiate the comparative 'most effective'.

This over-translation is where scientific findings are regularly converted into non-scientific advertising. The study itself is usually solid; the popular representation of the study is usually overreaching.

What this method is for

The aim of this checklist is not to disqualify every peptide study. On the contrary: a cleanly read study is substantially more useful than one translated into marketing language. With this methodology one can recognise what a finding actually shows — and what it does not show. Knowing both is the basis of an informed assessment.

On peptide.journal every data object and every article tries to make this separation visible: what the study shows stands in the facts section, possible over-extensions are pointed out in the caveat. That is editorial hygiene — and the condition for this platform to remain useful as a serious information offering.